Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNAP trial for Staphylococcus aureus bloodstream infection management
ISRCTN17997749Phase 4Enrolling by invitation
- Sponsor
- University College London
- Start
- Nov 2023
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
01
Overview
Phase 4, randomised, open-label trial of cefazolin, vancomycin, daptomycin, flucloxacillin, cloxacillin and 3 more in Staphylococcal bacteremia (10 arms), sponsored by University College London. Primary endpoints: All-cause mortality at 90 days and Paediatric composite outcome. Started Nov 2023; status: enrolling by invitation.
02
Drugs
cefazolinvancomycindaptomycinflucloxacillincloxacillin
03
Conditions
Staphylococcal bacteremia
Beyond the preview
Go deeper on ISRCTN17997749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17997749.